Cognition Therapeutics, Inc. provided consolidated earnings guidance for the year ended December 31, 2023. For the year, the company expected net loss to be approximately $25.6 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | +2.56% | 0.00% | +8.11% |
Jun. 07 | Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target | MT |
May. 29 | HC Wainwright Starts Cognition Therapeutics With Buy Rating, $10 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.11% | 78.11M | |
+18.03% | 125B | |
+13.36% | 108B | |
-7.24% | 24.21B | |
+2.10% | 22.78B | |
-10.77% | 17.96B | |
-41.74% | 16.43B | |
-12.81% | 16.37B | |
+1.06% | 13.58B | |
+27.23% | 11.66B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023